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Pasture-associated severe equine asthma (EPA) is a progressive condition affecting
horses in the southeastern United States. Pulmonary function testing with methacholine
challenge (MC) provides a definitive diagnosis by eliciting airway hyper-responsiveness.
Most horses require extensive conditioning to accept the instrumentation. Our hypothesis
was that MC protocols designed to elicit airway hyper-responsiveness would yield
equivalent results in the presence and absence of sedation. Sedated and unsedated MCs
were performed on 8 EPA-affected horses, with each horse acting as its own control.
Acepromazine was superior to xylazine/butorphanol, resulting in sedation and data
collection. Based on American Thoracic Society guidelines, an acceptable ability to
detect differences in lung resistance is less than a twofold difference in the provocative
concentration of methacholine that elicited a 40% increase in lung resistance (PC40RL).
Significant differences in PC40RL were not detected. Validation of a sedation protocol for
use in MC will expand the application of this diagnostic.
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SEVERE EQUINE ASTHMA
Nomenclature
Severe equine asthma previously known as “heaves”, recurrent airway
obstruction, and chronic obstructive pulmonary disease, is a naturally occurring disease
that predominantly affects middle-aged horses1–6. Two subtypes exist and are named
based on the environment that exacerbates clinical signs: barn dust-associated severe
equine asthma and pasture-associated (i.e., pasture asthma) severe equine asthma2,4,7.
Barn dust asthma occurs in horses in temperate climates spending the majority of their
time stabled4. Pasture asthma occurs in horses housed on pasture during the warm months
in the southeastern United States and United Kingdom7–9.
Clinical Signs and Disease Prevalence
Clinical signs of Severe Equine Asthma include increased respiratory rate and effort,
nostril flare, coughing, and respiratory distress. Affected horses may adopt an extended
neck posture, become inappetent, and suffer severe weight loss. The disease is chronic
and progressive and early in the disease course can present with seasonal signs of
nonspecific exercise intolerance that make definitive diagnosis difficult.
Equine pasture asthma (EPA) is a disease characterized by airway hyperresponsiveness, bronchoconstriction, smooth muscle hyperplasia, and goblet cell
metaplasia with mucus accumulation and neutrophilic inflammation of the lower
1

respiratory tract5,7,9–12. Onset of clinical disease is associated with environmental changes
including increases in temperature, dew point temperature, humidity, grass pollen, and
mold spores8. Hypersensitivity to aeroallergens including molds and pollens is presumed
based upon the temporal association of clinical disease with these allergens1,7,8,13. It is
estimated that approximately 3-5% of horses in the southern United States are affected
with EPA8. In the United Kingdom, it has been estimated that up to 50% of EPA affected
horses also have clinical signs consistent with the barn dust asthma subtype but this
observation is not congruent with the fact that barn dust-associated asthma is quite
uncommon in the southeastern United States12.
Common Diagnostics
The diagnosis of EPA is suspected when a history of warm season recurring respiratory
compromise with intervening periods of cool season clinical remission is present along
with evidence of neutrophilic inflammation in bronchoalveolar lavage fluid (BALF) or
transtracheal wash (TTA)8–10. Transtracheal wash samples may contain up to 90% nondegenerate neutrophils and be mucopurulent in appearance1,4. However, concurrent
pneumonia should always be ruled out. Endoscopic examination of these horses
frequently reveals tracheal mucus1. More chronically affected horses may have a
thickened carina and experience dynamic airway collapse during endoscopy1. A BALF
neutrophil percentage of greater than 20-25% is consistent with a diagnosis of severe
equine asthma14. However, a recent study suggests that not all horses with severe asthma
meet or exceed the neutrophil threshold on airway fluid samples15. In this study the
horses with the most clinically severe disease had BALF neutrophil percentages of
<20%15. Bullone et al suggest that the severe small airway pathology and mucostasis
2

present in advanced disease contribute to an obstructive physiology. This results in an
inability to sample these most affected airways and a falsely low neutrophil percentage15.
Complete blood counts in clinically affected horses are frequently normal or may have
mild non-specific changes including a mild mature neutrophilia and an increase in
fibrinogen9. A recently described technique utilizing a histopathologic scoring system for
endobronchial biopsy samples correlates well with impulse oscillometry but only during
periods of clinical exacerbation16. These challenges coupled with the seasonal nature and
complete remission of clinical signs highlight the limitations of many of the common
diagnostics employed to diagnose severe equine asthma. Early diagnosis and appropriate
intervention are necessary to delay disease progression.
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PULMONARY FUNCTION TESTING
Conventional Pulmonary Mechanics
Pulmonary function testing in conjunction with methacholine challenge provides an
objective method to document the presence, severity, and reversibility of airway hyperresponsiveness in horses17,18. This is particularly helpful for diagnosis during seasonal
disease remission and early in the disease course when signs are mild. The classical
method and current gold standard for pulmonary function testing is referred to as
Conventional Pulmonary Mechanics and involves the insertion of an esophageal balloon
attached to a catheter for measuring transpulmonary pressure19. Horses must wear a face
mask that encompasses their muzzle to approximately the level of the infraorbital
foramen for the duration of the testing. To ensure accurate measurements an elastic
“girdle” attached to the mask must fit snugly against the horse’s face and extends 3-4cm
above the mask creating an air tight seal. A pneumotachograph is fitted to the mask to
measure airflow. Measures of pulmonary function commonly acquired from conventional
mechanics include resistance of the lung (RL), dynamic compliance (Cdyn), elastance (E),
and maximal change in pleural pressure (∆Pplmax). Using these measurements, it is
possible to monitor changes in pulmonary mechanics in real time both at rest and in
response to a variety of drugs (methacholine, histamine, levalbuterol). Horses
experiencing bronchoconstriction have an increase in RL and ∆Pplmax and a decrease in
4

Cdyn and E. Though our research horses have been trained to pulmonary function testing
using operant conditioning, not every horse has the temperament to accept the
instrumentation while unsedated. As with many equine diagnostic procedures, the use of
sedation could facilitate methacholine challenge in clinical patients. However, sedation
has been demonstrated to alter airway caliber and decrease ventilation20–23. These effects
call into question the validity of pulmonary function testing in the presence of sedation.

Impulse Oscillometry
An alternative method of pulmonary function testing is impulse oscillometry. This
method was adapted for use in horses and is the preferred technique for non-compliant
human patients24. A non-compliant patient is considered one that regardless of the reason
cannot follow the directions to perform forced expiratory maneuvers24. Briefly, impulse
oscillometry uses a high-frequency signal to determine respiratory impedance and is
independent of respiratory rate19. As with conventional pulmonary mechanics, horses
must wear an air-tight mask with a pneumotachograph throughout the testing protocol19.
The primary variable from this system is impedance25. Impedance is determined by the
resistance, elastance, and inertance of the respiratory tract in response to oscillatory
frequencies25. In one study comparing the two techniques, impulse oscillometry was
considered more sensitive19. However, the data obtained cannot be directly compared as
the variables measured and resulting calculations are different19.
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Methacholine Challenge
Methacholine is a synthetic choline ester that acts as a non-selective muscarinic
receptor agonist in the parasympathetic nervous system26. When inhaled, methacholine
causes constriction of peripheral and central airways26. Methacholine along with
carbachol, histamine, prostaglandin, and leukotrienes are considered direct stimulants for
bronchoconstriction26. Direct stimulants initiate airway smooth muscle contraction by
binding with local receptors (i.e. muscarinic, histaminic)27–29. Indirect stimulants include
adenosine, bradykinin, metabisulfite, exercise, hypertonic aerosols, hypotonic aerosols,
isocapnic hyperventilation, mannitol, and propranolol26. Indirect stimulants result in the
activation of intermediate pathways28,30. Many of the end products of these pathways are
inflammatory mediators which then elicit bronchoconstriction28,30.
Bronchoprovocation with methacholine was first described in 194526. The
procedure is widely used in human medicine and has been employed in veterinary
clinical medicine and as a research procedure to identify and quantify abnormal
constriction responses of the airways19,24,28,31. In 2007 a revision of the 1999 ATS
guidelines was published focusing on testing in non-compliant asthmatics, specifically
toddlers24,32. In this article a greater than 40% increase in baseline lung resistance during
a methacholine challenge was proposed as the end point for diagnosis of asthma32. Based
on these recommendations Hunter et al demonstrated the utility of this end point in
identifying horses with airway hyperresponsiveness33. This tendency, termed airway
hyper-responsiveness, is a diagnostic feature of human asthma 24. In human asthmatics,
the degree of airway hyper-responsiveness correlates with disease severity34–38.
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Compliant asthmatics in human medicine are diagnosed via spirometry with
methacholine challenge24. A baseline forced expiratory volume(FEV) is measured by
spirometer and then methacholine is nebulized to the patient24. The FEV is acquired again
after the dose of methacholine and another dose of methacholine administered24. This
procedure is repeated until there is a > 20% decrease in FEV24.
There are two protocols published and regulated by the American Thoracic
Society for administration of a methacholine challenge: five-breath dosimeter protocol
and two-minute tidal breathing protocol24. The five-breath technique requires inhalation
of 5 doses of methacholine: 0.025, 0.25, 2.5, 10, and 25mg/ml24. Changes in pulmonary
function are quantified following each dose. While in humans, the advantage of this
protocol is the rapidity with which it can be completed, it necessitates the use of actuated
nebulizers which have not been validated for horses24. Also, the large changes in dose
concentration make it difficult to ascertain a specific provocative dose of methacholine24.
The second method utilizes doubling doses of methacholine starting at 0.03-0.0625
mg/ml that are inhaled for two minutes during normal tidal breathing until a threshold of
small airway constriction is achieved24. In human asthmatics, the dose of methacholine
that elicits a 20% decrease in forced expiratory volume (PD20) has been determined to be
the most accurate method for quantifying the magnitude of airway hyperresponsiveness24. In noncompliant humans, who are unable to generate forced expiratory
maneuvers, the dose of methacholine that elicits a 40% increase in lung resistance has
been employed for evaluating airway hyper-responsiveness32. The achievement of a 40%
increase in baseline resistance signifies the end point of this procedure. The final two
concentrations of methacholine administered and the percent increase in resistance from
7

baseline to each of these doses is calculated. These values are then utilized to calculate
the PC40RL which represents the concentration of methacholine required to achieve a
40% increase in lung resistance. Employing the 40% threshold from noncompliant
humans, in our laboratory, Hunter et al. demonstrated that horses with EPA reliably
demonstrate airway hyper-responsiveness characterized by a 40% increase in baseline RL
at provocative concentration of methacholine <1 mg/ml33. Interestingly, this threshold has
been previously considered diagnostic of moderate to serve human asthma (< 1 mg/ml)24.
Like non-asthmatic humans, normal horses fail to respond to methacholine doses up to 8
mg/ml17,24
A challenge to the diagnosis of EPA is that affected horses undergo a period of
disease remission during winter months when they appear clinically normal9. During
remission, these horses are frustrating to identify. To address this dilemma, we have
identified methacholine hyperresponsiveness in horses with EPA during disease
remission (preliminary data Figure 1)17. This substantiates that methacholine challenge
can be used as a diagnostic modality to identify horses with EPA regardless of clinical
status. An impediment to performing methacholine challenge in horses, which is
foundational to this work, is that few horses readily accept the necessary instrumentation
for the 40-minute procedure.
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EFFECTS OF SEDATION ON RESPIRATORY PHYSIOLOGY
Alpha-2 adrenoreceptor agonists
There are two types of adrenergic receptors, alpha and beta39,40. Alpha adrenergic
receptors are further subdivided into α1, α2A, α2B, and α2C-40. α2-adrenergic receptors are
located pre and post-synaptically and mediate a variety of responses40. Agonism of presynaptic receptors results in vasodilation, decreased gastrointestinal motility, and
inhibition of norepinephrine, epinephrine, and substance P40. Agonism of post-synaptic
receptors causes sedation, analgesia, vasoconstriction, and inhibition of insulin release40.
Centrally located α2-adrenergic receptors in the locus coeruleus are responsible for the
analgesia and sedation associated with administration of α2-adrenergic agonist drugs40,41.
The resulting effects on the cardiorespiratory system are bradycardia, hypotension, and
bradypnea40. These parameters slowly return to baseline after administration40.
The effects of the α2-adrenergic agonist xylazine on pulmonary function testing with
conventional mechanics were investigated in equine asthma affected and normal horses20–
22

. When administered to ponies in a barn-dust associated model exhibiting clinical signs

of bronchoconstriction, xylazine decreased RL and increased Cdyn. Changes in pulmonary
function were not detected in control and in diseased ponies during clinical remission20.
These findings indicate that xylazine dilates airways if bronchoconstriction is preexisting.
9

Additional investigations have determined that increases in total airway resistance
with xylazine are predominantly referable to increases in upper airway resistance and
altered head position21,22. In a study comparing the airway dynamics of horses sedated
with xylazine before and after placement of a nasotracheal tube, it was found that prior to
placement of the tube, total airway resistance, upper airway resistance and pressure,
respiratory work and pulmonary pressure were significantly increased compared to presedation21. However, after placement of a nasotracheal tube in these same sedated horses,
significant decreases in total airway resistance, upper airway resistance, and upper airway
pressure were seen21. A study looking at the effects of head position after xylazine
administration, on conventional pulmonary mechanics, reported an increase in pulmonary
pressure, upper airway resistance, and lower airway resistance at low head position22.
When the head position was neutral the resistance decreased significantly22. While this
contrasts the effect of methacholine, which increases lung resistance predominantly in the
lower airways, by inducing bronchoconstriction, lowering of the head position during
sedation and associated decreases in lung resistance would confound the measurement of
methacholine induced increases in lung resistance42.
Only one previous study has reported the effects of detomidine alone on conventional
pulmonary mechanics43. In this study, incremental dose escalation resulted in decreased
dynamic compliance and respiratory rate43. Detomidine in combination with butorphanol
was evaluated and resulted in decreased respiratory rate, minute volume, and maximal
change in pleural pressure23. Dynamic compliance and lung resistance were not
significantly different23.
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This indicates that α2-adrenergic agonists have the potential to be relevant during
methacholine challenge so long as head position, which has a large impact on upper
airway resistance, is constant22. This would also suggest that methacholine is preferable
to histamine for bronchoprovocation because histamine precipitates upper airway edema,
which increases the contribution of upper airway resistance to total resistance44.

Opioids
There are three major classes of opioid receptor: µ, κ, and δ45,46. Morphine is a pure
µ-agonist47. Pure µ-agonists are uncommonly utilized in equine medicine due to central
nervous system excitation and delayed gastrointestinal motility47–49. Butorphanol is
commonly administered in horses and is a µ-antagonist and κ-agonist47,49. Drugs that
provide sedation and analgesia via κ-agonism have less impact on gastrointestinal
motility48.
Butorphanol has not been evaluated as a sole agent for its effect on airway caliber in
horses. When administered alone in standing horses butorphanol resulted in excitation
without significant cardiopulmonary effects, including no alteration in respiratory rate50.
Butorphanol is frequently combined with an α2-adrenergic agonist to ameliorate CNS
excitation47. Administration of α2-adrenergic agonists potentiates the respiratory
depressant effects associated with some opioids47. Morphine co-administered with
xylazine caused a significant decrease in respiratory rate but not blood gas parameters in
healthy, standing horses51. When butorphanol was administered in combination with the
α2-adrenergic agonist romifidine, PaCO2 increased significantly, but no other blood gas
parameters were affected52. Sedation with the combination of butorphanol, and the potent
11

α2-agonist detomidine, decreased ventilation in both control and horses with recurrent
airway obstruction, without altering measures of lower airway caliber (Cdyn together with
RL) nor tidal volume as measured by conventional pulmonary mechanics23. There was
also a significant decrease in minute ventilation and ΔPplmax in diseased horses relative to
controls in this investigation23. However, in anesthetized dogs and rabbits instrumented
for conventional pulmonary mechanics, butorphanol administration did not elicit
significant differences from baseline resistance, predicting, congruent with the prior
investigation, that butorphanol is unlikely to alter airway caliber in horses53,54.
Cardiopulmonary effects of variable doses of buprenorphine, a partial agonist at the OP3
receptor, used in combination with xylazine were evaluated but its effects on airway
caliber were not evaluated55. Respiratory rate was significantly decreased up to 45
minutes post drug administration but there were no significant changes in blood gas
parameters55.

Phenothiazine neuroleptics
Acepromazine is a phenothiazine neuroleptic tranquilizer that antagonizes central and
peripheral post-synaptic dopaminergic receptors21,2256. Cholinergic, serotonergic,
muscarinic, histaminic, and alpha-adrenergic receptors are variably antagonized21,22,57.
The reticular activating system is depressed21,22. To date there are no studies describing
the effects of acepromazine when administered alone on conventional pulmonary
mechanics. In a 1988 study, respiratory curves were utilized as an indicator of respiratory
depth based on the difference between central venous pressure during inspiration and
expiration58. Acepromazine resulted in a significant decrease in respiratory rate and no
12

change in respiratory depth58. When xylazine was administered 20 minutes later the
respiratory rate decreased again and the respiratory depth increased58. Acepromazine is
frequently used in multi-drug protocols for sedation and anesthesia58–61. In these studies
acepromazine minimally affected gas exchange parameters58,61. Acepromazine prior to
upper airway endoscopy decreased abduction of the left arytenoid62.
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EQUINE ESOPHAGEAL INNERVATION AND MOTILITY
The body of the esophagus consists of two muscular layers63. The outer muscular layer
has longitudinal fibers and the inner layer has circumferential fibers63. The distal third of
the equine esophagus is comprised of smooth muscle and the proximal two thirds is
composed of skeletal muscle63. Three types of motility occur in the esophagus64–66.
Primary peristalsis results from a stimulus originating in the oropharynx and upper
esophageal sphincter64,65. Secondary peristalsis results from distention of the esophageal
body, for example a remaining food bolus64,65. Tertiary peristalsis only occurs in smooth
muscle64,65. Central and peripheral control mechanisms are responsible for esophageal
motility with acetylcholine acting as the major stimulating neurotransmitter via alphaadrenergic receptors64,65,67. The intrinsic plexi provide partial control of smooth muscle
motility via innervation by the vagus nerve which receives input from the swallowing
center64,65. Cholinergic influence is most prominent in the proximal smooth muscle and
decreases distally64,65. The inherent latency gradient in the esophagus is decreased by
cholinergic nerve stimulation64,65. Manipulation of this gradient changes the speed of
peristalsis64,65.
Contrast radiography studies revealed that detomidine but not acepromazine
causes changes in esophageal motility68,69. In a study measuring esophageal manometric
pressures xylazine/ butorphanol and detomidine significantly and dramatically decreased
14

the number of spontaneous swallows70. Acepromazine also decreased the number of
swallows but less significantly70. The profound effect of xylazine/butorphanol and
detomidine may have resulted from the accompanying CNS depression and reduction in
response to normal mechanical and chemical swallowing triggers70. Detomidine and
acepromazine increased the number of high-pressure events in the distal esophagus70.
Xylazine and butorphanol increased the number of spontaneous and high-pressure events
in the esophagus70.

15

METHODOLOGY
Rationale
Several factors support the rationale that methacholine challenge will be valid in sedated
horses. First, commonly employed sedatives (xylazine and detomidine) that exert mild
bronchodilation during clinical exacerbation of recurrent airway obstruction are α2 adrenergic receptor agonists, whereas methacholine induces bronchoconstriction via
muscarinic receptor signaling1,7. Second, methacholine challenge is routinely employed
to demonstrate airway hyper-responsiveness in sedated and anesthetized animals2-4.
Third, the methacholine challenge protocol employed determines the quantity of
methacholine required to achieve a 40% increase in baseline airway resistance,
effectively negating differences in baseline airway caliber and rate of methacholine
inhalation caused by sedation1.

Hypothesis and Objectives
The central hypothesis of this work is that methacholine challenge protocols that elicit
a defined threshold change in airway caliber (relative to the baseline airway caliber) will
yield equivalent results in the presence and absence of sedation1. This is irrespective of
any increase or decrease in baseline airway caliber or decrease in the rates of
methacholine inhalation caused by sedation. The first objective was to determine a
16

sedation protocol. The second objective was to compare the concentration of
methacholine that elicited a 40% increase in RL in sedated and unsedated horses with
Equine Pasture Asthma. To address these objectives and increase the feasibility of
methacholine challenge in clinical patients, we first performed a pilot study comparing
the effect of combined xylazine and butorphanol to acepromazine alone, on the
provocative concentration of methacholine that induces a 40% increase in lung resistance
(PC40RL) using a two-minute tidal breathing protocol developed for methacholine
challenge in noncompliant human asthmatics1. With the proper sedation protocol defined,
we next addressed our primary aim: to compare the provocative concentration that causes
a 40% increase in baseline pulmonary resistance in sedated and non-sedated horses. As
changes in the provocative concentration for methacholine challenge less than two
doubling doses are not considered clinically relevant in assessing the efficacy of human
asthma therapeutics with methacholine challenge, we hypothesize that the PC40RL in the
sedated and unsedated state will be within two doubling doses of each other11.

Animals
Eight adult horses previously diagnosed by methacholine challenge with Equine
Pasture Asthma including four mares and four geldings were used in the study. Three of
these horses were initially used in the pilot study to determine our sedation protocol. The
procedure was repeated on all eight horses with the final sedation protocol. Each horse
was determined to be in clinical remission by the primary investigator based on physical
examination parameters and a clinical score of respiratory effort (CSRE) of ≤310. Horses
were brought in from pasture for the procedure and returned to pasture immediately after
17

data collection. No horse had been administered any medications for at least one month
prior to use in this study. Procedures were performed with the approval of the
Institutional Animal Care and Use Committee.

Pilot Study
Three horses were administered xylazine (0.1 mg/kg IV) and butorphanol (0.01
mg/kg IV) 15 minutes prior to instrumentation for conventional pulmonary mechanics.
Data collection was successful in one of these horses and unsuccessful in two, due to
increased esophageal peristaltic waves (Figure 1). These waves interfered with data
collection and prevented completion of the methacholine challenge protocol. This
sedation protocol was deemed unacceptable. A new protocol, utilizing acepromazine, was
designed and tested in three horses. Acepromazine (.01mg/kg) was administered 15
minutes prior to instrumentation. All three horses successfully completed the
methacholine challenge protocol, achieving >40% increase in lung resistance.

Conventional Pulmonary Mechanics Instrumentation
Horses were instrumented for the measurement of conventional pulmonary mechanics
as previously described. The horse was measured from the nares to the 10-13th intercostal
space and the distance marked on a rigid fluoropolymer catheter. An esophageal balloon
was secured over this catheter which was passed through the nares to the level of the
mark. The mark represented the thoracic esophagus between the heart and cardiac
sphincter. The catheter-balloon unit was then placed in line with a pressure transducer
18

(DP 45-28, Validyne Corp) to monitor pleural pressure7-10. The balloon was uniformly
filled with air across all tests to optimize pressure signals, which are initially recorded for
2-3 minutes to insure proper placement and pressure values consistent with the magnitude
of respiratory effort. The catheter was manipulated to improve waveforms (absence of
cardiac deflections and wave forms with negative deflection during inspiration), so the
exact final location of the balloon was unknown. The balloon had to remain caudal to the
heart as the ventricular motion interfered with pleural pressure waveforms. Flow was
measured using a Fleisch #5 pneumotachograph and transducer (DP 45-14, Validyne
Corp) fitted into a mask (Aeromask, Trudell International) that sealed to the horse’s face
and covered the nares, while minimizing dead space. Maximal change in pleural pressure
(ΔPplmax) and total pulmonary resistance (RL), and dynamic compliance (Cdyn) were
measured as the average of 15 representative breaths using Buxco Systems Biosystems
XA software (v. 2.5). Measurement of these parameters in horses has been well
described,7-10 and is technically straight forward in horses that are trained to accept the
instrumentation.

Methacholine Challenge and Data Collection
Methacholine challenge was performed using the 2-minute tidal breathing protocol as
described in guidelines by the American Thoracic Society with nebulized doses from
0.03125mg/ml – 8 mg/ml1. The nebulizer (Pari LC-Star reusable nebulizer) and air
compressor (Pari ProNeb Turbo) were standardized for consistent administration.
Baseline maximal change in pleural pressure (ΔPplmax) and total pulmonary resistance
(RL), were determined from 15-20 breaths at rest and following nebulization of 0.9%
19

saline. A target of 40% increase in pulmonary resistance was calculated using the below
equation (5.1) and doubling doses of methacholine were serially administered via
nebulization in 5-minute intervals.
RL Target = (0.4 * RL Baseline) + RL Baseline

(5.1)

Between each methacholine dose, 15-20 representative breaths were recorded,
and the challenge was discontinued at the methacholine concentration that increased RL
>40% above baseline RL. During the methacholine challenge, the average RL for each
dose of methacholine was calculated from the data collected. This prevented horses from
receiving additional methacholine doses after the target RL was reached. Following
methacholine challenge, 1.25mg of levalbuterol was administered via nebulization to
reverse bronchospasm, which was confirmed by improvements in ΔPplmax, RL, and Cdyn at
7- and 15-minutes post nebulization.
Each horse underwent two methacholine challenges, one sedated and one
unsedated, allowing each horse to act as its own control. For the sedated methacholine
challenge, acepromazine (0.05-0.1mg/kg based on primary investigator’s discretion) was
administered intravenously 15 minutes prior to instrumentation. Following
instrumentation, baseline data was collected and repeated in 2 minutes. The horse’s head
position and height were noted by two trained observers during baseline collection. The
same observers monitored the horse’s head position and height throughout the procedure.
If the horse’s head height and position changed during data collection, external stimuli
were provided until the head returned to the baseline position (i.e. the head was not
manually repositioned). The methacholine challenge was commenced as previously
described with the final dose of methacholine causing ≥ 40% increase in baseline RL .
20

Each horse was then nebulized levalbuterol to reverse methacholine induced
bronchoconstriction.

Data Analysis
The last two concentrations of methacholine administered were used to manually
𝑙𝑜𝑔 𝐶1)(40 – 𝑅1)
calculate a PC40RL. PC40RL = antilog [log C1 + (𝑙𝑜𝑔 𝐶2 – 𝑅2−𝑅1
] (5.2)

This equation was modified from the equation utilized to calculate the FEV20. In this
equation C1 represents the second-to-last methacholine concentration, C2 the final
concentration of methacholine (dose resulting in ≥ 40% increase in RL from baseline), R1
the percent rise in RL after C1, and R2 the percent rise in RL after C2.

(RLN- RLB/ RLB) * 100

(5.3)

In the above modified percent increased equation, RLN represents the measured resistance
after administration of the ultimate or penultimate methacholine dose. RLB represents the
baseline resistance.
The PC40RL of the unsedated and sedated methacholine challenges for an
individual horse were compared. Under the American Thoracic Society guidelines, when
comparing two PC40RL from the same individual, if the results are within two double
doses(4 times) of each other they are considered not significantly differently. The
unsedated PC40RL was used to establish the two doubling dose range in this study. A twotailed T-test for 2 dependent means was performed with an α <.01.

21

RESULTS
Sedated and non-sedated pulmonary function testing and methacholine challenge
were well tolerated by all horses. Each horse was monitored by the primary investigator
for signs of sedation prior to instrumentation. Horses demonstrated a lower head position,
relaxed ear posture, decreased response to environmental stimuli, slower gait, and hind
limb toe dragging. No adverse effects to the sedative were observed.

Xylazine and Butorphanol Protocol
Three horses were sedated with xylazine and butorphanol. During baseline data
collection, frequent, irregularly-shaped, tall, peaked, pressure waves occurred from the
pleural pressure (i.e. esophageal pressure) catheter (Figure 6.1). These waves interfered
with data collection. Two of the three methacholine challenges initiated under the
xylazine and butorphanol protocol could not be completed due to these abnormal waves
from the pleural pressure (i.e. esophageal pressure) catheter. Inability to collect the
pleural (esophageal pressure) data precluded the use of xylazine and butorphanol sedation
for methacholine bronchoprovocation.
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Figure 6.1

Sample baseline esophageal pressure and airflow waves from a horse with
EPA that was sedated with xylazine and butorphanol.

The above image demonstrates intrapleural pressure (red) and airflow (blue) waves
generated by Buxco Xa software from the baseline data of a horse sedated with xylazine
and butorphanol. Each blue waveform is the equivalent of one respiratory cycle
(inspiration and expiration). The red line should have a waveform appearance as
indicated in the top panel of Figure 6.2 and the two waveforms should overlap for each
breath. In this image there are pressure tracings that have no relationship to the
respiratory cycle, including waves that are narrow and tall, and which have multiple
oscillations which are not associated with changes in flow. These unusual waves
precluded the ability to attain useful data. The waveforms were monitored for 45minutes
with no change in frequency or character of the pressure tracing.

Acepromazine Protocol
All acquired data sets from 8 horses administered acepromazine sedation were
complete and yielded pleural pressure waves that were in phase with flow. The abnormal
pressure waves described under the xylazine and butorphanol protocol were infrequent
and did not prevent data collection (Figure 6.2).
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Figure 6.2

Pleural pressure and flow waves collected with the acepromazine protocol
in a horse with EPA

The top image represents ideal wave forms during data collection. The flow (blue line)
and intrapleural pressure (red line) tracings should overlap. The rise in esophageal
pressure (positive deflection) and air flow correlates with expiration and the decrease
(negative deflection) with inspiration. The small bump during the expiratory phase
indicates an expiratory pause and is common in horses. The bottom image represents the
infrequent abnormal pressure waves that occurred with acepromazine sedation but did not
prevent data collection or the completion of a methacholine challenge
All eight horses showed a dose response to nebulization of doubling doses of
methacholine. A representative response to methacholine challenge in a horse in the
absence of sedation and again during sedation is presented in Figure 6.3. Consistent with
the presence of airway hyper-responsiveness, all eight horses reached their target RL at a
concentration of methacholine less than 8mg/ml (Table 6.1). The highest dose of
methacholine administered was 2mg/ml during a sedated challenge. Each horse was then
confirmed to return to or below the baseline RL after nebulization of levalbuterol.
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Sedated vs. non-sedated methacholine challenge comparison in a single
horse with EPA

The x-axis represents the stages of the methacholine challenge. Starting with acquisition
of a baseline, denoted as “mask”, followed by nebulization of saline as a control,
increasing mg/ml doses of methacholine until the target is reached, and lastly
nebulization of levalbuterol. The y-axis provides the calculated average RL associated
with each challenge stage.

The sedated PC40RL for each horse was within two doubling doses of the
unsedated PC40RL (Table 6.1 and Figure 6.4). Three of the horses had a sedated PC40RL
that was less than their unsedated PC40RL and five horses had a PC40RL that was greater
than their unsedated PC40RL. The average and median unsedated PC40RL were 0.19 and
0.175, respectively. The average and median sedated PC40RL were 0.25 and 0.27,
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respectively. The two tailed t-test with dependent means yielded a t value of 1.81. The
value of p was 0.11. This supports the conclusion that the results of the two challenges
were not significantly different.

Table 6.1
Horse
1
2
3
4
5
6
7
8

Sedated and unsedated PC40RL from 8 horses with EPA
PC40RL Acceptable
Range
0.090 – 1.440
0.030 – 0.480
0.038 – 0.600
0.013 – 0.208
0.050 – 0.800
0.060 – 0.960
0.035 – 0.552
0.068 – 1.080

PC40RL Unsedated

PC40RL Sedated

0.360
0.120
0.150
0.052
0.200
0.240
0.138
0.270

0.350
0.280
0.100
0.068
0.430
0.330
0.201
0.260

Calculated PC40RL for sedated and unsedated methacholine challenge are indicated for
each horse tested. The acceptable range for PC40RL is calculated by multiplying (high
end) or dividing (low end) the unsedated PC40RL by 4 or two doubling doses.
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Figure 6.4

Sedated

Comparison of sedated and unsedated PC40RLfrom 8 horses with EPA

The x-axis represents the 8 individual horses used in the study. The y-axis represents
PC40RL. The black bar indicates the allowed two-doubling dose range. The blue circles
represent the unsedated PC40RL and the red dash the sedated PC40RL.
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CONCLUSION
Discussion
Acepromazine provided adequate sedation, was well-tolerated by all horses, and
did not interfere with data collection or results during pulmonary function testing with a
methacholine challenge. The differences between the PC40RL calculated from unsedated
and sedated challenges were less than two doubling doses of each other which is not
considered clinically relevant under the American Thoracic Society guidelines24. The
American Thoracic Society is the organization responsible for providing gold standards
for diagnosis of asthma in humans.
Horses presenting in seasonal remission or early in the disease, present a
significant diagnostic challenge. Many of the commonly utilized diagnostics have nonspecific or normal results under these circumstances. Identifying and initiating proper
environmental and medical management as early as possible is key to delaying disease
progression. Identification of horses at high risk of having pasture-associated severe
equine asthma, based upon positive methacholine bronchoprovocation during the season
of clinical disease remission, also provides an adjunctive testing modality for horses
being considered for purchase in the southeastern United States during this time period.
However, due to its progressive nature, need for radical management changes, and
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frequent need for administration of systemic corticosteroids, this is not a diagnosis that
can be made without consequence.
This validation of a sedation protocol for methacholine challenge in horses
expands the population of horses who are candidates for this procedure. Previously,
horses have needed extensive training and the right temperament to tolerate the
instrumentation and testing environment. This limited the use of this diagnostic to
extensively conditioned horses in small research herds. This study demonstrated the
utility of sedated methacholine challenge, providing additional data proving that horses in
seasonal remission maintain elicitable airway hyper-responsiveness. All the horses in this
study met the target RL after administration of ≤ 1mg/ml methacholine. Humans who
respond at these low concentrations are categorized as having moderate-severe asthma24.
Five of the eight horses required an additional dose of methacholine during the
sedated challenge compared to the unsedated challenge. Respiratory rate depression is a
common side effect of sedation in horses. We hypothesize that this caused these five
horses to inhale a lower amount of methacholine during the prior steps of the tidal
breathing protocol. However, congruent with our hypothesis, differences in the PC40RL
between sedated and non-sedated horses were within the two doubling doses, which is
not considered to be clinically significant in evaluations of human asthma.
Another common side effect of sedation is a decreased head-to-ground height.
This increases upper airway resistance and changes airway dynamics22. As anticipated,
during this study, it was observed that as a horse’s head lowered, RL increased. If the
horse was stimulated and returned to the original head position, RL would return to the
previous level. If the horse’s head position became higher during the procedure, then RL
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decreased. The observed differences were significant and would dramatically change the
target RL for the methacholine challenge. Due to this observation, the horse’s head
position was marked during acquisition of baseline parameters. For the remainder of the
procedure it was monitored continuously by two handlers to ensure it was consistent
throughout the entire procedure.
Abnormal pressure waves, associated especially with the administration of
xylazine and butorphanol, were unanticipated and severely affected the procedure,
preventing useable data collection. The waves were persistent for 45 minutes after
instrumentation, at which time the procedure was discontinued in two horses. After
thorough review of the literature, it was hypothesized that this sedation protocol induced
secondary esophageal peristaltic waves. The combination of xylazine and butorphanol
has been shown to markedly decrease spontaneous swallowing70. This is most likely due
to profound central nervous system depression and thus depression of the swallowing
center70. When a food bolus remains in the body of the esophagus and cannot be cleared
by primary peristalsis that is initiated by swallowing, secondary peristalsis is initiated64,70.
It has been previously proposed that pooling saliva in sedated horses can be a trigger for
secondary peristalsis 70. In the current study, instrumentation for acquisition of
intrapleural pressure required placement of an esophageal balloon in the thoracic
esophagus. We hypothesize that this balloon may have provided the same sensory
stimulus as a food bolus or pooling saliva resulting in peristalsis. Since the balloon was
attached to a catheter that was secured to the horse’s mask and immovable, the stimulus
would have been continuous and have the potential to elicit the strings of high pressure
waves that were observed. It is noteworthy that these waves were also observed after
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administration of acepromazine but were infrequent. Additionally, acepromazine has
been shown to only mildly decrease spontaneous swallowing in horses70.

Limitations
The major limitation of this study is that it was performed in horses extensively
conditioned to accept pulmonary function testing. Horses not accustomed to the
instrumentation may require higher doses of acepromazine to safely perform the
procedure. Since, secondary peristaltic waves were present in the horses in this study they
may become more frequent with higher doses of acepromazine. This could limit the use
of this diagnostic completely, if useable data cannot be collected. A higher dose could
also impact the amount of methacholine needed to reach the target RL and significantly
alter the testing outcome. Future studies should be performed on horses with no prior
experience with pulmonary function testing.
A second limitation of this study was that no normal horses were used in the
population as a true control. While these horses could have provided useful information
about the true effect of acepromazine on the parameters monitored during pulmonary
function testing, the doses of methacholine necessary to achieve PC40RL in normal horses
are not known. This would be additionally useful as there is very little literature on the
respiratory effects of acepromazine in horses as a sole agent. However, normal horses fail
to respond to methacholine doses up to 8 mg/ml, a threshold congruent with nonasthmatic humans33. Accordingly, it is quite possible that doses of methacholine
necessary to achieve PC40RL in normal horses could be detrimental to human handlers.
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The last significant limitation of this study was the small population size. The
horses utilized in this study have advanced disease and may have introduced bias into the
result. Given the wide range of disease severity, a larger population size that reflected the
disease spectrum would provide additional merit to the current findings.
Conclusion
The present study is a useful addition to the Severe Equine Asthma literature as it
provides a sedation protocol for use with conventional pulmonary mechanics and
methacholine challenge. The PC40RL comparisons provide the first evidence that it is
possible to replicate the dose of methacholine that elicits a threshold level of airway
contraction in the same unsedated and sedated horses. This not only expands the
population of horses available to participate in methacholine bronchoprovocation in
research studies, but also provides an alternative diagnostic modality for clinical cases
with pasture-associated severe equine asthma that are being evaluated during in seasonal
disease remission.
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